Generic drug industry needs to stand up for patient safety

Although makers of brand-name drugs have strict requirements about risk warnings, the same doesn't apply to generic drugs. But the FDA is trying to level the playing field.

The Generic Pharmaceutical Assn. says a proposed federal regulation that would allow makers of generic drugs to inform people about all known health risks would create "dangerous confusion" and have "harmful consequences for patients."

And why would that be?

For the answer, the industry group pointed me toward a recent report from Matrix Global Advisors, an independent consulting firm. The report says the rule change would needlessly complicate the market and add $4 billion a year to already bloated healthcare costs.

ASK LAZ: Smart answers to consumer questions

 

"Higher insurance premiums, self-insurance costs and reserve spending on product liability will likely force generic drug manufacturers to raise prices," said Alex Brill, the head of Matrix and the report's author. "Generic manufacturers also may exit or decline to enter the market for products with greater liability risk."

It's not until you reach the last page of the Matrix report that you discover it was "sponsored" — that is, paid for — by the Generic Pharmaceutical Assn.

As my colleague David G. Savage reported last week, generic drug makers are pulling out all the stops to fight the Food and Drug Administration's attempt to provide consumers with more information about the possible risks of prescription drugs.

One would think any move to improve drug safety would be welcomed by all concerned. After all, nobody wants a costly lawsuit related to misuse of a prescription med or an unforeseen side effect.

In this case, though, the $240-billion U.S. generic drug industry has long enjoyed different (read: looser) rules than those applied to brand-name drugs. And it likes things just as they are.

"They'll fight anything that could add to their costs," said Mindy Marks, a health economist at UC Riverside. "That's why we have an FDA — to make sure consumers have enough information to make informed decisions about drugs."

Makers of brand-name drugs have strict requirements about risk warnings. Just think about all those fast-talking voices at the end of commercials for everything from heart medications to pills that promise to make a man more of a man.

The same doesn't apply to generic drugs, and you can thank the five conservative justices on the U.S. Supreme Court for that.

They decided in 2011 that generic-drug companies don't share the same level of responsibility as makers of brand-name equivalents to update their warning labels when a new risk comes to light.

The conservative justices followed this bizarre ruling with an even stranger 5-4 decision last year. They said that because generic makers are just following brand-name makers in their use of ingredients, patients can't sue them even if their product is found to be harmful.

In response, the FDA came up with a modest rule change that would help level the playing field. It would empower generic makers to update their warning labels any time new risks become known, rather than wait for federal authorities to require a change.

"More than 80% of prescriptions filled in the U.S. are for generics, so we want to make sure that generic drug companies actively participate with the FDA to ensure that product safety information is accurate and up to date," said Janet Woodcock, director of the agency's Center for Drug Evaluation and Research.

Seems reasonable enough.

Let's say a big company makes baby cribs. And let's say smaller companies manufacture copycat cribs.

If a potentially dangerous design flaw becomes known, you'd think all producers of these cribs have a responsibility to inform consumers. And, by the same token, you'd think all such companies are legally accountable for the products they sell.

Featured Stories

CTnow is using Facebook comments on stories. To comment on ctnow.com articles, sign into Facebook and enter your comment in the field below. Comments will appear in your Facebook News Feed unless you choose otherwise. To report spam or abuse, click the X next to the comment. For guidelines on commenting, click here.

CONSUMER COLUMNISTS

Kevin Hunt - The Electronic Jungle

Kevin Hunt: Technology for the amateur spy - July 21, 2014 - Spy technology has become so widespread and smartphone-ready that sleuthing, like golf, can be played by almost anyone.

Gail MarksJarvis

Investors focus on earnings, not Ukraine, Gaza Strip - July 23, 2014 - After a few jitters over the crises in the Middle East and Ukraine, investors have used last week's stock market sell-off to buy stocks at...

David Lazarus

Patients throw cold water on cost for post-op cooling device - July 24, 2014 - Why treat someone with a $200 medical device when you can get similar results with a $17,500 gadget?

Korky Vann

Hot Or Cold, Lobster Rolls Are Worth The Drive - July 13, 2014 - At least once a summer, (more often, if I'm lucky), I have to have a lobster roll — preferably consumed at a picnic table with a...

Advertisement

...